GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Capex-to-Operating-Income

Benevolent AI (Benevolent AI) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Benevolent AI's Capital Expenditure for the three months ended in Dec. 2023 was $-0.52 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-45.52 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Benevolent AI Capex-to-Operating-Income Historical Data

The historical data trend for Benevolent AI's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Capex-to-Operating-Income Chart

Benevolent AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Benevolent AI Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only - - 0.01 - -

Competitive Comparison of Benevolent AI's Capex-to-Operating-Income

For the Biotechnology subindustry, Benevolent AI's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benevolent AI's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Capex-to-Operating-Income falls into.



Benevolent AI Capex-to-Operating-Income Calculation

Benevolent AI's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.399) / -96.858
=N/A

Benevolent AI's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.522) / -45.516
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benevolent AI  (GREY:BAIVF) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Benevolent AI Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Benevolent AI (Benevolent AI) Business Description

Comparable Companies
Traded in Other Exchanges
Address
4-8 Maple Street, London, GBR, W1T 5HD
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.